Addition of oxaliplatin to folinic acid-modulated fluorouracil extended survival in pancreatic cancer

  • July 22, 2014

The addition of oxaliplatin to second-line treatment with folinic acid and fluorouracil significantly extended OS and time to progression in patients with advanced gemcitabine-refractory pancreatic cancer, according to results of a randomized, open-label phase 3 study.

The findings support the recommendation of the regimen as standard for this patient population, according to researchers.

Full Story »

Personalize your page!

Register for Healio to get content tailored to your specialty and areas of interest. It’s FREE and only takes one minute. Register now!

More»
More»
More»
More »
  • Financial Planning
  • RUDZINSKI COLUMN
  • Advice for physicians
  • Be aware of important 2014 IRA updates. Analysis by Certified Financial Planner Ken Rudzinski.
More »
HemOnc Today